Carbamic acid, 1H-benzimidazol-2-yl-, methyl ester, sulfate (1:1) | 23424-63-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并咪唑类
• 英文名称: Carbamic acid, 1H-benzimidazol-2-yl-, methyl ester, sulfate (1:1)
• 英文别名: methyl N-(1H-benzimidazol-2-yl)carbamate;sulfuric acid
• CAS: 23424-63-7
• 化学式: C9H11N3O6S
• 分子量: 289.27
• InChiKey: IIMPDLKQWSJLCO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.09
• 重原子数：
  19
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.11
• 拓扑面积：
  150
• 氢给体数：
  4
• 氢受体数：
  7

文献信息

• WEAK BASE SALTS
  申请人：Arizona Board of Regents, acting on behalf of the University of Arizona

  公开号：EP1606290A1

  公开（公告）日：2005-12-21
• Weak base salts
  申请人：Yalkowsky H. Samuel

  公开号：US20070043070A1

  公开（公告）日：2007-02-22

  Pharmaceutical compositions comprising a salt of a weak base compound of formula: wherein X is hydrogen, halogen, alkyl of less than 7 carbon atoms or alkoxy of less than 7 carbon atoms; n is a positive integer of less than 4; Y is hydrogen, chlorine, nitro, methyl, ethyl or oxy-chloro; R is hydrogen, alkylaminocarbonyl wherein the alkyl group has from 3 to 6 carbon atoms or an alkyl group having from 1 to 8 carbons and R2 is 4-thiazolyl, NHCOOR1 wherein R, is aliphatic hydrocarbon of less than 7 carbon atoms, or an alkyl group of less than 7 carbon atoms; one or more free acids; and optional pharmaceutical additives are provided.
• [EN] WEAK BASE SALTS<br/>[FR] SELS DE FAIBLE BASICITE
  申请人：UNIV ARIZONA

  公开号：WO2004081006A1

  公开（公告）日：2004-09-23

  Pharmaceutical compositions comprising a salt of a weak base compound of formula: wherein X is hydrogen, halogen, alkyl of less than 7 carbon atoms or alkoxy of less than 7 carbon atoms; n is a positive integer of less than 4; Y is hydrogen, chlorine, nitro, methyl, ethyl or oxychloro; R is hydrogen, alkylaminocarbonyl wherein the alkyl group has from 3 to 6 carbon atoms or an alkyl group having from 1 to 8 carbons and R2 is 4-thiazolyl, NHCOOR1 wherein R, is aliphatic hydrocarbon of less than 7 carbon atoms, or an alkyl group of less than 7 carbon atoms; one or more free acids; and optional pharmaceutical additives are provided.